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. In their article, the authors provide a comprehensive overview of the current understanding of the interaction between dietary intake and the composition of the gut microbiota and its role in the regulation of blood pressure. They summarize several human studies showing that the human gut microbiome in patients with hypertension harbours lower microbial diversity and an increased Firmicutes:Bacteroidetes ratio accompanied by decreases in acetateproducing and butyrate-producing bacteria 2, 3 . Interestingly, similar changes in the microbiome are also observed in genetic animal models of hypertension 2, 4, 5 . Although these observations cannot prove causality, targeted modification of the gut microbiota might be a novel adjunct treatment strategy for hypertension. Interventions such as oral antibiotic treatment 2,5 and a high-fibre diet 6 have been shown to attenuate high blood pressure and rebalance the dysbiotic gut microbiome in various hypertensive rodent models.
Modulation of the gastrointestinal intraluminal milieu by selective pharmacological inhibition of intestinal absorption of dietary ions, glucose, fat, or proteins might offer an alternative approach to control the gut microbiome. The proximal colon is an important site of dietary ion absorption. Sodium uptake is critically regulated by the sodium/hydrogen exchanger 3 (NHE3). Previously, we showed that pharmacological inhibition of intestinal NHE3 using an orally nonabsorbable, specific NHE3 inhibitor increased faecal sodium excretion and water content. This change was associated with a sustained reduction in systolic blood pressure and attenuation of cardiac hypertensive end-organ damage in hypertensive rats 6, 7 . Although we did not study the microbiome after gut-restricted NHE3 inhibition, modulation of the intraluminal intestinal milieu might be a promising approach to influence the composition of gut microorganisms. Importantly, nonabsorbable and, therefore, nonsystemic drugs have fewer off-target systemic effects and, consequently, less drugdrug interaction and toxicity, and fewer adverse effects. Further studies are needed to investigate the feasibility and efficacy of altering the gut microbiome composition by oral treatment with nonabsorbable drugs specifically targeting ion transporters such as NHE3 or sodium/glucose cotransporter 1 in the gut.
